ÇØ´ç ÄÁÆÛ·±½º´Â Á¾·áµÇ¾ú½À´Ï´Ù.
Conference Programs

- Display of Biologics
»ý¹°Á¦Á¦ÀÇ Àü½Ã - Engineering Antibodies
Ç×üÀÇ ¿£Áö´Ï¾î¸µ - Machine Learning: Part 2
±â°èÇнÀ(ÆÄÆ® 2)

- Antibody-Based Therapies
Ç×ü ±â¹Ý Ä¡·á¹ý - Emerging Targets & Approaches
»õ·Î¿î Ç¥Àû°ú ¾îÇÁ·ÎÄ¡ - Membrane Protein Targets
¸·´Ü¹éÁú Ç¥Àû

- Safety & Efficacy
¾ÈÀü¼º°ú È¿´É - Advancing Multispecifics
´ÙÁ߯¯À̼ºÇ×üÀÇ Áøº¸ - Engineering Bispecifics
ÀÌÁ߯¯À̼ºÇ×üÀÇ ¿£Áö´Ï¾î¸µ

- Modulating the TME
TME(Á¾¾ç ¹Ì¼¼È¯°æ)ÀÇ Á¶Àý - Innovative CAR T Therapy
Çõ½ÅÀûÀÎ CAR-T ¿ä¹ý - Next-Gen Immunotherapies
Â÷¼¼´ë ¸é¿ªÄ¡·á

- Optimisation & Developability
ÃÖÀûÈ¿Í ¹ßÀü¼º - Analytical Characterisation
ºÐ¼® Ư¼º Æò°¡ - Protein Stability & Formulation
´Ü¹éÁú ¾ÈÁ¤¼º°ú ¹èÇÕ

- Data Science & Engineering
µ¥ÀÌÅÍ »çÀÌ¾ð½º¿Í ¿£Áö´Ï¾î¸µ - Optimising Expression
¹ßÇöÀÇ ÃÖÀûÈ - Process Development
ÇÁ·Î¼¼½º °³¹ß

- Intro to Machine Learning
±â°èÇнÀ ÀÔ¹® - Machine Learning: Part 1
±â°èÇнÀ(ÆÄÆ® 1) - Machine Learning: Part 2
±â°èÇнÀ(ÆÄÆ® 2)

- Antibody-Based Therapies
Ç×ü ±â¹Ý ¿ä¹ý - Engineering Conjugates
º¹ÇÕüÀÇ ¿£Áö´Ï¾î¸µ - Next-Gen Immunotherapies
Â÷¼¼´ë ¸é¿ªÄ¡·á